Abstract:Dopamine receptors are therapeutic targets for the treatment of various neurological and psychiatric disorders, including Parkinson's and Alzheimer's. Previously, PF-06649751 (tavapadon), PF-2562 and PW0464 have been discovered as potent and selective G protein-biased D1/D5 receptor agonists with optimal pharmacokinetic properties. However, no selective D5R agonist has been reported yet. In this context, we designed and synthesized forty non-catecholamines-based pyrimidine derivatives and identified four pyrimidine derivatives as selective D5R partial agonists. Using cAMP-based GloSensor assay in transiently transfected HEK293T cells with human D1 or D5 receptors, we discovered that compound 5c (4-(4-bromophenyl)-6-(2,4,5-trimethoxyphenyl)pyrimidin-2-amine) exhibited modest D5R agonist activity. This leads us to explore various modifications of this scaffold to improve the D5 agonist potency and efficacy. Using molecular docking, and rational design followed by their evaluation at D1 and D5 receptors for agonist activity, we identified three new derivatives, 5j, 5h, and 5e. The most potent compound of this series 5j (4-(4-iodophenyl)-6-(2,4,5-trimethoxyphenyl)pyrimidin-2-amine), exhibited EC50 of 269.7 ± 6.6 nM. Mice microsomal stability studies revealed that 5j is quite stable (>70 % at 1 hr). Furthermore, pharmacokinetic analysis of 5j (20 mg/kg, p.o) in C57BL/6j mice showed that 5j is readily absorbed via oral route of dosing and also enters into the brain (plasma Tmax: 1 h, Cmax: 51.10 ± 13.51 ng/ml; Brain Tmax: 0.5 h, Cmax: 22.54 ± 4.08 ng/ml). We further determined the in-vivo effect of 5j on cognition in scopolamine-induced amnesia in C57BL/6j mice. We observed that 5j (10 mg/kg, p.o) alleviated scopolamine-induced impairment in short-term memory and social recognition, which were blocked by D1/D5 antagonist SCH23390 (0.1 mg/kg, i.p.). Furthermore, 5j did not exhibit any cytotoxicity (up to 10 µM) or in vivo acute toxicity up to 200 mg/kg (p.o). These results strongly suggest that 5j could be further developed for treating neurological disorders wherein the D5 receptors play pivotal roles.

Identification of N-propylnoraporphin-11-yl 5-(1,2-dithiolan-3-yl)pentanoate As a New Anti-Parkinson's Agent Possessing a Dopamine D2 and Serotonin 5-HT1A Dual-Agonist Profile.

Synthesis and Pharmacological Investigation of Novel 2-Aminothiazole-privileged Aporphines

(6Ar)-11-amino-n-propyl-noraporphine, A New Dopamine D-2 and Serotonin 5-Ht1a Dual Agonist, Elicits Potent Antiparkinsonian Action and Attenuates Levodopa-Induced Dyskinesia in A 6-Ohda-lesioned Rat Model of Parkinson'S Disease

Synthesis of dihydrofuroaporphine derivatives: Identification of a potent and selective serotonin 5-HT1A receptor agonist

Further SAR Study on 11-O-substituted Aporphine Analogues: Identification of Highly Potent Dopamine D3 Receptor Ligands

Identification of Novel 1-O-substituted Aporphine Analogues As Potent 5-HT2C Receptor Agonists

Identification of a New Series of Potent Adenosine A2A Receptor Antagonists Based on 4-Amino-5-carbonitrile Pyrimidine Template for the Treatment of Parkinson's Disease.

Lead Optimization of 4-Acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines As A(2a) Adenosine Receptor Antagonists for the Treatment of Parkinson'S Disease

Structural Optimizations and Bioevaluation of N-H Aporphine Analogues As Gq-biased and Selective Serotonin 5-HT2C Receptor Agonists.

N-Propylnoraporphin-11-O-yl Carboxylic Esters As Potent Dopamine D2 and Serotonin 5-HT1A Receptor Dual Ligands

Chemistry And Pharmacological Characterization Of Novel Nitrogen Analogues Of Amop-H-Oh (Sazetidine-A, 6[5-(Azetidin-2-Ylmethoxy)Pyridin-3-Yl]Hex-5-Yn-L-Ol) As Alpha 4 Beta 2-Nicotinic Acetylcholine Receptor-Selective Partial Agonists

Structure activity relationship studies of 6α- and 6β-indolylacetamidonaltrexamine derivatives as bitopic mu opioid receptor modulators and elaboration of the 'message-address concept' to comprehend their functional conversion.

Novel 1-(Prop-2-yn-1-ylamino)-2,3-dihydro-1h-indene-4-thiol Derivatives As Potent Selective Human Monoamine Oxidase B Inhibitors: Design, SAR Development, and Biological Evaluation.

Optimization of 6-Heterocyclic-2-(1h-pyrazol-1-yl)-n-(pyridin-2-yl)pyrimidin-4-amine As Potent Adenosine A2A Receptor Antagonists for the Treatment of Parkinson's Disease.

Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives As Μ/κ Opioid Receptor Dual Selective Ligands.

5-HT1A Receptor Agonist 8-OH-DPAT Improves Dyskinesias in Parkinson's Disease by Mitigating GluR1Ser831 Phosphorylation

Discovery of Indolylpiperazinylpyrimidines with Dual-Target Profiles at Adenosine A2A and Dopamine D2 Receptors for Parkinson's Disease Treatment.

Further structure-activity relationships study of hybrid 7-{[2-(4-phenylpiperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol analogues: identification of a high-affinity D3-preferring agonist with potent in vivo activity with long duration of action.

Synthesis and Structure-Activity Relationships of 5'-Aryl-14-alkoxypyridomorphinans: Identification of a Mu Opioid Receptor Agonist/Delta Opioid Receptor Antagonist Ligand with Systemic Antinociceptive Activity and Diminished Opioid Side Effects.

Discovery and structure - activity relationships of 2,4,5-trimethoxyphenyl pyrimidine derivatives as selective D5 receptor partial agonists

Dual Ligands Targeting Dopamine D2 and Serotonin 5-HT1A Receptors As New Antipsychotical or Anti-Parkinsonian Agents.